Jumbo Drug Bank

Jumbo Drug Bank is a clinical-stage biotechnology company based in Chengdu, China, focused on the discovery and development of innovative small molecule therapeutics for infectious diseases and oncology. Founded in 2019 by leading scientists from Sichuan University, the company is advancing a robust pipeline led by JDB0131 (WXWH0131), a novel nitroimidazole entering Phase 2b clinical trials for the treatment of multidrug-resistant tuberculosis (MDR-TB). In addition to its anti-tuberculosis program, Jumbo Drug Bank is developing targeted oncology therapies, including the MNK inhibitor JDB175 for B-cell lymphomas and JDB153 for advanced solid tumors. The company maintains strong research ties with Sichuan University and collaborates closely with WestVac Biopharma to accelerate its clinical development programs.